Nanobodies that bind a component of the SARS-CoV-2 replication complex
Professors Piergiorgio Percipalle and Gennaro Esposito summarise their study which revealed two nanobodies that could inhibit a non-structural protein of SARS-CoV-2.
List view / Grid view
Professors Piergiorgio Percipalle and Gennaro Esposito summarise their study which revealed two nanobodies that could inhibit a non-structural protein of SARS-CoV-2.
Dr Pushpanathan Muthuirulan explores why messenger RNA (mRNA) is advantageous for vaccine development and how the COVID-19 pandemic has accelerated its progress within the pharmaceutical industry.
Scientists have found that SARS-CoV-2 can knock out an important molecular pathway linked to an immune complex called MHC class I.
The new study used sequence clustering analysis to identify four subgroups of COVID-19 to help match patients to specific treatments.
Scientists used a new screen to identify FAM72A as a cause of mutagenesis that affects antibody development in COVID-19 and cancer.
Everest Medicines and Providence Therapeutics have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant.
A novel antiviral drug called thapsigargin (TG) blocked COVID-19 infection in cells, including all new variants, in a pre-clinical study.
Researchers discover a new precision strategy to hinder the infection of the coronavirus, leading to the filing of a new drug patent.
The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.
A new study claims that future COVID-19 vaccines should activate T cells to attack infected cells expressing replication proteins.
The intestine chip was infected with a coronavirus to test a variety of drugs, presenting a new method to investigate COVID-19 treatments.
Scientists revealed five proteins that cause blood vessel damage in COVID-19 patients, potentially leading to new drug targets.
Neutralising monoclonal antibodies protected aged macaque monkeys from SARS-CoV-2 and reduced inflammation, including in cerebrospinal fluid, a new study has shown.
The La Jolla Institute for Immunology and Brigham and Women's Hospital will collaborate to develop a pan-coronavirus vaccine.
Researchers have shown that a new microneedle vaccine patch was 10 times stronger at generating an immune response in animals than a subcutaneous injection.